Diabetes Practice Guidelines for Primary Care

Objectives

The guidance sets out a primary-care framework for preventing, detecting and managing diabetes, with emphasis on lifestyle modification, patient education, individualised clinical targets, appropriate medicines and prevention of complications.[1]It focuses on screening, diagnosis, treatment and clinical assessment rather than setting out a broader population-health mission, budgeted strategic framework or named programme areas.[2][3][4]

• Promote nutrition support, regular physical activity, smoking cessation, limited alcohol consumption, diabetes self-management education and weight reduction where appropriate.[1]
• Individualise glycaemic goals according to age, health status, complications and risk of hypoglycaemia, while generally aiming for glycated haemoglobin (HbA1c) below 7%, blood pressure below 130/80 mm Hg and low-density lipoprotein cholesterol below 100 mg/dl.[1]
• Detect diabetes early by screening adults without identified risk factors every three years after age 40 and screening people with specified risk factors annually, using fasting plasma glucose as the recommended screening test.[2]
• Classify glucose status using fasting plasma glucose, two-hour plasma glucose and casual plasma glucose thresholds for normal glucose status, impaired fasting glucose or impaired glucose tolerance, and diabetes.[2]
• Prevent and identify complications through renal disease prevention, retinal assessment, foot examination, cardiovascular assessment and monitoring for albuminuria or proteinuria.[1][3]
• Address the substantial diabetes burden identified in the Bahamas, where the 2019 STEPS Survey estimated adult prevalence at approximately 11.6% and indicated that prevalence rises with age.[1]

Implementation

Delivery is centred on structured primary-care assessment, lifestyle and self-management support, stepwise pharmacotherapy, regular complication screening and escalation to specialist or higher-level care when clinical findings warrant it.[1][2][3]The treatment algorithm draws on the HEARTS protocol, American Diabetes Association guidance and National Institute for Health and Care Excellence guidance.[4]

• Assess medical and family history, nutrition and physical activity, medicine use, tobacco and alcohol use, immunisation status and depression, alongside physical examination and laboratory testing.[5]
• Undertake initial, routine and annual examinations covering weight, waist circumference, blood pressure, cardiopulmonary and cardiovascular status, foot health, fundoscopy, skin and oral health, and monofilament and vibration testing.[5][3][4]
• Provide nutritionist or dietitian referral, a planned physical-activity programme, smoking-cessation support, diabetes self-management education, blood-glucose monitoring education and medicine management.[1]
• Use metformin as first-line treatment, sulfonylurea as second-line treatment and human insulin as third-line treatment, considering specialist referral before insulin is initiated.[2][3]
• Consider thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists where standard medicines cannot be used; these alternatives are generally more costly than metformin, sulfonylurea and insulin, and the guidance describes evidence of superior effectiveness as currently limited.[3]
• Monitor blood pressure at every scheduled visit, arrange retinal examinations at diagnosis and at least every two years thereafter, examine feet at each visit, assess lower-limb amputation risk annually and test for proteinuria annually.[3]
• Monitor blood glucose, HbA1c, lipid levels, urinary albumin, serum creatinine and urinalysis, assessing HbA1c every three months for people not at goal and repeating abnormal urinary albumin results after three to six months.[1][5]
• Respond to abnormal findings through self-management education, medicine adjustment, improved glycaemic control, statin therapy, possible fibrate treatment for hypertriglyceridaemia, and endocrinology, nephrology or higher-level referral when indicated by glycaemic, lipid, albuminuria or proteinuria findings.[1][3]
• Manage severe hypoglycaemia and severe hyperglycaemia with the specified immediate interventions, including hospital referral for severe hyperglycaemia.[3]
• Support care through diabetes-team management and increased patient contact.[1]

The material specifies clinical intervals, targets and referral triggers but does not specify formal programme governance, stakeholder roles beyond clinical teams and referral services, a reporting platform, accountability structure, evaluation timetable, budget, financing mechanism or resource-mobilisation plan.[1][5][2][3]

Monitoring & Evaluation

Monitoring centres on routine clinical assessment, laboratory testing and treatment adjustment for people with diabetes in primary care. Core measures include blood glucose, glycated haemoglobin (HbA1c), lipid levels, urinary albumin, serum creatinine, urinalysis, blood pressure, weight and waist circumference.[5]Glycaemic goals are generally individualised, with an HbA1c target below 7%, alongside blood-pressure and low-density lipoprotein cholesterol targets that may be adjusted for age, overall health, complications and hypoglycaemia risk.[1]

• Measure HbA1c every three months for people who are not meeting glycaemic goals.[1]
• Screen adults without recognised risk factors every three years after age 40, and screen people with specified risk factors annually, using fasting plasma glucose as the recommended screening test.[2]
• Classify glucose status using specified fasting, two-hour and casual plasma-glucose thresholds for normal glucose status, impaired fasting glucose or impaired glucose tolerance, and diabetes.[2]
• Monitor blood pressure at every scheduled visit and assess cardiovascular status as part of routine physical examination.[3][5]
• Conduct retinal examination at diagnosis and at least every two years thereafter, including fundoscopy within the wider examination schedule.[3][5]
• Examine feet at each visit, assess lower-limb amputation risk annually, and use monofilament and vibration testing within scheduled foot assessment.[3][5]
• Test annually for proteinuria and urinary albumin, recheck abnormal urinary albumin findings after three to six months, and assess renal function using serum creatinine, urinalysis and related laboratory investigations.[3][5]
• Review medical and family history, nutrition, physical activity, medication use, tobacco and alcohol use, immunisation status and depression as part of assessment.[5]
• Respond to abnormal findings through diabetes self-management education, medication adjustment, improved glycaemic control, lipid-lowering treatment where indicated and referral to endocrinology, nephrology or higher-level care for specified abnormalities.[1][3]

The monitoring approach is primarily patient-level and clinically oriented. It includes referral triggers for albuminuria, glycaemic and lipid findings, as well as immediate management and hospital referral for severe hyperglycaemia.[1][3]The source identifies an estimated adult diabetes prevalence of approximately 11.6% in the Bahamas in the 2019 STEPS Survey and notes increasing prevalence with age.[1]

A separate programme reporting framework, surveillance platform, aggregate performance indicators, evaluation timetable and formal accountability structure are not specified.[1][5][2][3]

Costing & Financing

No budget, costing estimate, funding allocation, financing arrangement, funding source, resource-mobilisation mechanism or quantified funding gap is specified.[1][5][2][3]The material nevertheless identifies service inputs that would require health-system capacity, including laboratory testing, routine examination, retinal and foot assessment, patient education, nutrition support, physical-activity support, medication management and specialist referral.[1][5][3]

• Use metformin as first-line treatment, sulfonylurea as second-line treatment and human insulin as third-line treatment, with specialist referral considered before insulin initiation.[2][3]
• Recognise that thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are generally more costly than metformin, sulfonylurea and human insulin.[3]
• Consider the more costly alternative medicines when standard medicines cannot be used; the excerpt notes limited evidence that they provide superior effectiveness.[3]
• Support delivery through diabetes-team management, increased patient contact and referral to nutritionists or dietitians, endocrinologists and nephrologists where clinically indicated.[1]

No monetary values, currency, economic assumptions, cost-effectiveness estimates, procurement arrangements or expenditure periods are provided.[1][5][2][3]